Первая клетка. И чего стоит борьба с раком до последнего

DeVita V. T., Jr. et al. Clinical Cancer Research: The Past, Present and the Future. Nature Reviews Clinical Oncology. 11, no. 11 (2014): 663–669.

Horgan J. Sorry, but So Far War on Cancer Has Been a Bust. Scientific American, May 21, 2014.

El-Deiry W. S. Are We Losing the War on Cancer? Cancer Biology & Therapy. 14, no. 12 (2013): 1189–1190.

Davis D. The Secret History of the War on Cancer. New York: Basic Books, 2007.

Scannell J. W. et al. Diagnosing the Decline in Pharmaceutical R&D Efficiency. Nature Reviews Drug Discovery. 11 (2012): 191–200.

Chandrasekar Th. Why Are We Losing the War on Cancer? 2018 European Society for Medical Oncology Congress (#ESMO18), October 19–23, 2018, Munich, Germany. www.urotoday.com/conference-highlights/esmo-2018/esmo-2018-prostate-cancer/107789-esmo-2018-why-we-are-losing-the-war-on-cancer.html

Ehrenreich B. Bright-Sided: How the Relentless Promotion of Positive Thinking Has Undermined America. New York: Metropolitan Books, 2009.

Baldwin J. Letter from a Region in My Mind. New Yorker, November 9, 1962.

DÖhne H. et al. Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel. Blood. 129 (2017): 424–447.

LeBlanc Th. W., Erba H. P. Shifting Paradigms in the Treatment of Older Adults with AML. Seminars in Hematology. 56, no. 2 (2019): 110–117.

Goldman J. M. Chronic Myeloid Leukemia: A Historical Perspective. Seminars in Hematology. 47, no. 4 (2010): 302–311.

Lo-Coco F., Cicconi L. History of Acute Promyelocytic Leukemia: A Tale of Endless Revolution. Mediterranean Journal of Hematology and Infectious Diseases. 3, no. 1 (2011): e2011067.

Mak I. W. et al. Lost in Translation: Animal Models and Clinical Trials in Cancer Treatment. American Journal of Translational Research. 6, no. 2 (2014): 114–118.

Wong Ch. H. et al. Estimation of Clinical Trial Success Rates and Related Parameters. Biostatistics. 20, no. 2 (2019): 273–286.

Lowe D. A New Look at Clinical Success Rates. Science Translational Medicine, February 2, 2018. https://blogs.sciencemag.org/pipeline/archives/2018/02/02/a-new-look-at-clinical-success-rates

Nixon N. A. Drug Development for Breast, Colorectal, and Non-Small Cell Lung Cancers from 1979 to 2014. Cancer. 123, no. 23 (2017): 4672–4679.

Hay M. et al. Clinical Development Success Rates for Investigational Drugs. Nature Biotechnology. 32 (2014): 40–51.

95 % of Promising Cancer Research Fails. Dying for a Cure, July 10, 2016.

http://dyingforacure.org/blogs/95-promising-cancer-research-fails/

Davis C. et al. Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009–13. BMJ. (2017): 359.

Kola I., Landis J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Reviews Drug Discovery. 3 (2004): 711–716.

Hay M. et al. Clinical Development Success Rates for Investigational Drugs. Nature Biotechnology. 32, no. 1 (2014): 40–51.

Thomas D. W. et al. Clinical Development Success Rates, 2006–2015.

www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006–2015 %20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf

Siegel R. L. et al. Cancer Statistics 2018. CA. 68, no. 1 (2018): 7–30.